Peter A. Kavsak, 1* Andrew R. MacRae, 2 Glenn E. Palomaki, 3 Alice M. Newman, 4 Dennis T. Ko, 4 Viliam Lustig, 2 Jack V. Tu, 4 and Allan S.
|
|
- Scot Daniel
- 5 years ago
- Views:
Transcription
1 Clinical Chemistry 52: (2006) Evidence-Based Laboratory Medicine and Test Utilization Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected Cohort of Troponin-Naïve Emergency Department Patients Peter A. Kavsak, 1* Andrew R. MacRae, 2 Glenn E. Palomaki, 3 Alice M. Newman, 4 Dennis T. Ko, 4 Viliam Lustig, 2 Jack V. Tu, 4 and Allan S. Jaffe 5 Background: In a population originally classified for acute myocardial infarction (AMI) by the World Health Organization (WHO) definition, we compared the health outcomes after retrospectively reclassifying with the European Society of Cardiology and the American College of Cardiology (ESC/ACC) AMI definition, using the peak cardiac troponin I (ctni) concentrations. The health outcomes were based on the WHO definition and occurred in an era that preceded the use of cardiac troponin biomarkers. Methods: For 448 patients who presented to the emergency department with symptoms suggestive of cardiac ischemia in 1996, we obtained data for all-cause mortality and recurrent AMI for up to 1 year after the initial presentation. We performed retrospective analysis of the patients frozen plasma samples to measure ctni (AccuTnI, Beckman Coulter). Results: At 30, 120, and 360 days, the risk for AMI/death in patients positive for AMI by only the ESC/ACC criteria was significantly lower than the risk in patients positive by both ESC/ACC and WHO criteria, and significantly higher than in patients negative according to both criteria. In a separate analysis, patients with a 1 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. 2 Department of Laboratory Medicine and Pathobiology and 4 Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, ON, Canada. 3 Department of Pathology, Women and Infants Hospital of Rhode Island, Providence, RI. 5 Cardiovascular Division and Division of Laboratory Medicine, Mayo Clinic, Rochester, MN. * Address correspondence to this author at: McMaster University Medical Centre, 1200 Main St. W., HSC 2N52, Hamilton, ON L8N 3Z5, Canada. Fax ; kavsakp@mcmaster.ca. Received May 11, 2006; accepted August 17, Previously published online at DOI: /clinchem peak ctni >0.10 g/l were at greater risk for AMI/death than patients with ctni concentrations of g/l. Patients negative by both definitions or with peak ctni concentrations <0.04 g/l had the highest eventfree survival rates (92% and 94%, respectively) at 1 year. Conclusion: In a troponin-naïve population, patients classified as positive for AMI by only the ESC/ACC criteria have a prognosis that appears to be intermediate between those classified positive by both the WHO and ESC/ACC definitions and those who meet neither criteria American Association for Clinical Chemistry In 2000, the European Society of Cardiology/American College of Cardiology (ESC/ACC) 6 modified the criteria defining acute myocardial infarction (AMI) to rely more substantially on measurements of a highly sensitive biomarker, cardiac troponin (ctn) (1). As expected, this newer definition resulted in an increased prevalence of AMI compared with the previous WHO criteria (2, 3); however, whether the risk of death or recurrent AMI in this newly defined AMI group was as high as for those diagnosed by the previous WHO criteria remained unclear (4, 5). Two reports provided early risk estimates. One study suggested an increased risk of all-cause mortality and the combined endpoint of cardiovascular death or nonfatal AMI for those with AMI defined by the ESC/ACC criteria (5). The other found no differences in 6 Nonstandard abbreviations: AMI, acute myocardial infarction; ESC, European Society of Cardiology; ACC, American College of Cardiology; ctn, cardiac troponin; ctni, cardiac troponin I; NN, negative according to both WHO and ESC/ACC definitions; NP, negative according to WHO definition and positive according to ESC/ACC definition; PP, positive according to both WHO and ESC/ACC definitions; STEMI, ST-segment elevation myocardial infarction; MI, myocardial infarction; AHA, American Heart Association. 2028
2 Clinical Chemistry 52, No. 11, major adverse cardiac events between the newly defined group and those meeting the criteria of both definitions (4). Neither study measured the relative risk of recurrent AMI alone for either group. The purpose of our study was to make an unbiased assessment of the risk of recurrent AMI and/or all-cause mortality in patients negative by both definitions, positive by both, or positive only by the ESC/ACC criteria. Because our study consisted of patients originally classified and treated in 1996 on the basis of the WHO criteria, without knowledge of the ctn concentrations, the results were not affected by currently available interventions such as percutaneous coronary intervention and antiplatelet therapies that are now commonly used in response to ctn increases (6). This type of study is important because it is not known whether the new ESC/ACC criteria led to identification of more low-risk AMI patients, thus improving the overall prognosis of AMI, or more high-risk patients, in which case the overall prognosis may deteriorate (4, 5). Evidence from an unbiased population is essential to allow for continued epidemiologic surveillance of populations. Furthermore, our retrospective measurement of ctni also allows a comparison of different ctni concentrations grouped according to published cutoff values (7). Materials and Methods patient selection The study population and its characteristics have been reported previously (8, 9). Briefly, the study cohort consisted of 448 unique patients who were enrolled in 1996 as part of an emergency department cardiac marker study at Oshawa General Hospital (now Lakeridge Health Oshawa). The study included all patients presenting with symptoms suggestive of cardiac ischemia as assessed by triage staff (8, 9). The leftover plasma specimens from 1996 were frozen at 70 C, with the exception of brief periods when they were at 20 C. In 2003, the specimens were thawed and analyzed for cardiac troponin I (ctni) by the AccuTnI assay (Beckman Coulter Inc.) without knowledge of the previous clinical diagnoses (8, 9). Specimen stability with the AccuTnI troponin assay after multiple freeze-thaw cycles has been well documented (10, 11). This study received research ethics approval. ami classification The WHO-based AMI group in our study population was obtained in 1996 by independent review of charts and creatine kinase isoenzyme MB (CKMB) mass biomarker concentrations by a cardiologist and a specialist in emergency medicine on the basis of the WHO MONICA (Multinational MONItoring of trends and determinants in CArdiovascular disease) project criteria (8). For the retrospective ESC/ACC diagnosis, we evaluated the peak ctni concentration in each patient against 2 cutoffs: the 99th percentile (0.04 g/l) and 10% CV (0.06 g/l). Concentrations exceeding the cutoff were classified as AMI positive (8, 9, 12). For 24% of our population (n 108) only 1 specimen, collected at presentation, was available, and the measured ctni of this specimen was considered the peak concentration. On the basis of the 99th percentile cutoff and the ESC/ACC definition for AMI, AMI was excluded in 307 of the 448 patients by both WHO and ESC/ACC criteria [negative according to both WHO and ESC/ACC definitions (NN); Fig. 1A]; 80 patients, all of whom had non ST-segment elevation myocardial infarction (STEMI), met only the ESC/ACC definition [negative according to WHO and positive according to ESC/ACC (NP)], and 60 patients met both definitions for AMI [positive according to both definitions (PP); this group included all 31 patients with STEMI]. Only 1 patient was classified as positive by the WHO definition and negative by the ESC/ACC definition. This patient had only 1 specimen measured, with CKMB 15 g/l and ctni 0.02 g/l; this result could reflect either a noncardiac source for CKMB or a sample obtained very soon after onset (13). The median ctni concentrations in the NN, NP, and PP groups were 0.01, 0.11, and 5.38 g/l, respectively. The 99th percentile is the desired cutoff for AMI classification (1, 14). The 99th percentile is derived from a reference control group that did not take sex into account. One study, however, has reported a sex difference in the 99th percentile with the AccuTnI assay (e.g., male 99th 0.10 g/l vs female 99th 0.04 g/l; P 0.034) (7). We therefore used the peak ctni concentrations to assemble our study cohort into 3 groups based on the lowest and highest reported 99th percentiles: a low-ctni group (i.e., ctni 0.04 g/l; also the manufacturer s indicated 99th percentile), an intermediate-ctni group (ctni g/l), and a high-ctni group (ctni 0.10 g/l). The median peak ctni concentrations and numbers of patients in the 3 groups were 0.01, 0.05, and 1.12 g/l in the low (n 284), intermediate (n 65), and high (n 99) groups, respectively. health outcomes Research ethics approval was granted to obtain all-cause mortality and recurrent AMI for up to 1 year after the initial presentation via linkage with the Canadian Institute for Health Information database (containing information on all hospital discharges in Ontario) and the registered persons database for mortality outcomes. The Canadian Institute for Health Information database has been validated as a source for obtaining myocardial infarction (MI) outcomes in Ontario hospitals (15). The database captures hospital discharge abstracts and includes information on sex, date of birth, date of hospital admission, admitting institution, and most responsible diagnosis, with the diagnoses coded via the International Classification of Diseases (9th revision) coding scheme (e.g., code for AMI is 410) (15).
3 2030 Kavsak et al.: Health Outcomes by AMI Definitions Fig. 1. Kaplan Meier curves for mortality from all causes and/or subsequent AMI. Among 448 patients stratified by 2 definitions of AMI (A), patients were stratified into 3 groups (NN, NP, and PP). Solid line indicates use of the 99th percentile cutoff level for ctni in the ESC/ACC criteria; dotted line indicates use of the 10% CV cutoff level for ctni in the ESC/ACC criteria. (B), ctni levels. Patients were stratified into 3 groups (low: peak ctni 0.04 g/l; intermediate: g/l; high: 0.10 g/l). statistical analysis All statistical analyses were performed with SAS, version Privacy constraints prohibit the display of cells from groups of 6 individual patients. A P value of 0.05 was considered statistically significant. Between-group comparisons of central tendency (means and medians) were based on 1-way ANOVA and the Kruskal Wallis test. The Pearson 2 test statistic was used to compare proportions unless the expected value was 5, in which case the Fisher exact test was substituted. Percentages were based on group totals, with the exception of readmission rates for AMI, for which the denominator was the number of patients who had not died up to the time point of interest. Time to an adverse event was assessed by Kaplan Meier survival curves with differences between groups determined by the log rank test. The Cox proportional hazard model was used for comparing adjusted survival curves (adjusted for age and sex). Logistic regression analysis (adjusted for age 65, time from onset of symptoms to hospital presentation of 6 h, sex, and previous MI) was performed to assess the role of ctni as a predictor of adverse outcome, with the odds ratio reflecting the strength of association and 95% confidence intervals indicating statistical significance if they did not include The C statistic, which is equivalent to the area under the ROC curve, was used to compare the predictive accuracy. The Kaplan Meier and Cox proportional hazard analyses were performed on the basis of the AMI groups (NN, NP, and PP) and the ctni groups (low, intermediate, and high). The Cox proportional hazard model was used for comparing adjusted survival curves of the PP, NP, and NN groups. The 99th percentile (ctni 0.04 g/l) was used to classify patients positive for AMI with the ESC/ ACC definition. In addition, hazard ratios were provided for the intermediate and high-ctni groups vs the low-ctni group. In a separate analysis, the Cox proportional hazard
4 Clinical Chemistry 52, No. 11, model was used for comparing adjusted survival curves of either the NP group or intermediate ctni group. The logistic regression analyses were performed with either the presentation or peak ctni concentration. Results The classification of our study population on the basis of the American Heart Association (AHA) definition, which is intended to be used for clinical and epidemiologic Variable Value Table 1. Study population. AHA case definition a n 228 At least 2 biomarker measurements b n Biomarker measurement n 98 P value Total population c n 448 Demographics Age at presentation Mean (SD) (12.97) (15.19) (15.29) (14.36) Median (IQR) 67 (56 76) 54 (46 72) 60 (49 73) (51 74) Sex, n (%) F 96 (42.1) 42 (37.8) 40 (40.8) (40.8) M 132 (57.9) 69 (62.2) 58 (59.2) 265 (59.2) Previous MI, n (%) No 162 (71.1) 90 (81.1) 77 (78.6) (75.2) Yes 66 (28.9) 21 (18.9) 21 (21.4) 111 (24.8) In-hospital course, n (%) Thrombolytic therapy No 209 (91.7) 107 (96.4) 97 (99.0) Yes 19 (8.3) 5 (3.6) 5 (1.0) ASA No 170 (74.6) 97 (87.4) 81 (82.7) (79.7) Yes 58 (25.4) 14 (12.6) 17 (17.3) 91 (20.3) Nitro No 96 (42.1) 74 (66.7) 71 (72.4) (55.1) Yes 132 (57.9) 37 (33.3) 27 (27.6) 201 (44.9) Length of hospital stay, days Mean (SD) 6.04 (7.36) 1.85 (4.67) 1.65 (3.53) (6.36) Median (IQR) 4 (2 7) 0 (0 0) 0 (0 2) (0 6) AMI Diagnosis, n (%) 1996 Expert Clinical Diagnosis No 182 (79.8) 105 (94.6) 91 (92.9) (86.4) Yes 46 (20.2) 6 (5.4) 7 (7.1) 61 (13.6) 1994 WHO MONICA (1 CKMB No 179 (78.5) 105 (94.6) 92 (93.9) (85.7) measurement 2XULN) Yes 49 (21.5) 6 (5.4) 6 (6.1) 64 (14.3) ESC/ACC 2000 (1 CKMB No 171 (75.0) 104 (93.7) 92 (93.9) (83.7) measurement 99th) Yes 57 (25.0) 7 (6.3) 6 (6.1) 73 (16.3) ESC/ACC 2000 (1 ctni No 126 (55.3) 92 (82.9) 83 (84.7) (68.8) measurement 99th) Yes 102 (44.7) 19 (17.1) 15 (15.3) 140 (31.3) ctni peak terciles ctni 0.04 g/l 110 (48.2) 88 (79.3) 79 (80.6) (63.4) ctni g/l 43 (18.9) 11 (9.9) 11 (11.2) 65 (14.5) ctni 0.10 g/l 75 (32.9) 12 (10.8) 8 (8.2) 99 (22.1) Group based on WHO and ESC/ACC definition NN negative for both NN 126 (55.3) 92 (82.9) 82 (84.5) (68.7) NP negative for WHO but NP 56 (24.6) 13 (11.7) 9 (9.3) 80 (17.9) positive for ESC/ACC PP positive for both PP 46 (20.2) 6 (5.4) 6 (6.2) 60 (13.4) Outcomes, n (%) Death within 30 d of presentation 6 (2.6) Death within 1 yr of presentation 29 (12.7) 7 (6.3) 10 (10.2) (10.3) Admitted for AMI within 30 d of 15 (6.8) presentation Admitted for AMI within 1 year of 29 (14.1) 6 6 (6.7) presentation Either death or AMI within 30 d 21 (9.2) 7 (6.3) 7 (7.1) (8.0) Either death or AMI within 1 year 52 (22.8) 10 (9.0) 14 (14.3) (17.4) a 2 specimens at least 6 h apart. Time interval between specimens 6 h. c Includes 11 patients who presented 24 h after onset of pain.
5 2032 Kavsak et al.: Health Outcomes by AMI Definitions research, is shown in Table 1 (2). The study population is presented as those patients who fulfilled the AHA definition of an adequate set of biomarkers, as well as those who did not have the minimum time length between specimens and those with only 1 specimen. For privacy reasons, values for the total columns are suppressed if any of the 3 groups consisted of 6 patients. Accordingly, the 11 patients with a self-reported onset of pain 24 h before presentation are not presented as a group. Only 51% of the patients (228 of 448; Table 1) conform to the AHA requirement of 2 specimens at least 6 h apart; the other half of our population had specimens collected with an interval 6 h, had only 1 specimen collected, or presented to the emergency department after 24 h from their selfreported onset of symptoms. For this reason, we opted to classify our population according to the maximum concentration of ctn, consistent with the ESC/ACC definition (1, 7). The Kaplan Meier curves constructed for the NN, NP, and PP groups (Fig. 1A) with the 99th percentile cutoff show clear differences in event-free (i.e., absence of AMI/ death) survival after 1 year between the 3 groups (92%, 70%, and 50%, respectively; P 0.001). The ctni cutoff concentrations of 0.04 g/l (99th percentile) and 0.06 g/l (10% CV cutoff) led to nearly identical outcomes, as expected from the proximity of these 2 cutoffs with this ctni assay. The groups classified according to peak ctni concentrations (low, intermediate, and high; Fig. 1B) also displayed differences in event-free survival after 1 year (low cutoff, 94%; intermediate cutoff, 75%; high cutoff, 55%; P 0.001). Cox proportional hazard modeling was used to compare adjusted survival curves of the AMI defined groups and the peak ctni groups (Tables 2 and 3). Setting either the NN group or the low-ctni group as the reference, both the NP and PP groups, or the intermediate and high-ctni groups, had significant hazard ratios for the combined endpoint of death/ami recurrence at 30, 120, and 360 days (Table 2). When the NP group or the intermediate ctni group was set as the reference, significant proportional hazards ratios associated with AMI recurrence and the combined endpoint of death or AMI occurred at 30, 120, and 360 days for the PP and high-ctni groups. In contrast, the NN and low-ctni groups were at less risk for the combined endpoint of death or AMI at 30, 120, and 360 days (Table 3). In our population, after we adjusted for age, sex, time from symptom onset to presentation, and history of previous MI, logistic regression analysis demonstrated that a peak ctni concentration 0.10 g/l was a strong predictor for both AMI recurrence and death at 1 year. Use of the presentation ctni values from our population in the analysis indicated that presentation ctni concentrations 0.04 g/l were also predictive of AMI recurrence at 1 year (Table 4). Discussion Our findings indicate that the newly defined AMI group under the ESC/ACC definition (i.e., the NP group: negative according to WHO criteria but positive according ESC/ACC criteria) have risks for adverse events that appear, for the most part, to be intermediate between the risks observed in the group negative for both ESC/ACC and WHO criteria (i.e., the NN group) and the group positive for both ESC/ACC and WHO criteria (i.e., the PP group) (Tables 2 and 3). Each category exhibited least a trend toward a significant difference, and for most outcomes, statistical significance was achieved. These data Days since presentation Table 2. Hazard ratios for the AMI positive groups (i.e., NP, PP groups and intermediate, high ctni groups). Outcome AMI classification Hazard ratio relative to NN (95% CI) Marker concentration ( g/l) Hazard ratio relative to ctni <0.04 g/l (95% CI) 30 Death NP 1.64 (0.45, 5.97) (1.02, 19.22) PP 2.12 (0.53, 8.49) (0.88, 15.74) AMI recurrence NP (2.22, 167) No events in ref. category PP (12.33, 703) 0.10 Death/AMI NP 4.21 (1.54, 11.52) (2.16, 34.21) PP (6.32, 35.73) (7.28, 80.39) 120 Death NP 4.86 (2.02, 11.69) (1.97, 16.99) PP 4.15 (1.50, 11.46) (2.42, 18.80) AMI recurrence NP 7.64 (1.88, 31.06) (1.31, 126) PP (13.64, 152) (11.98, 652) Death/AMI NP 6.55 (3.00, 14.33) (3.42, 28.18) PP (7.90, 34.00) (9.42, 61.42) 360 Death NP 2.89 (1.49, 5.60) (1.37, 6.43) PP 2.51 (1.13, 5.60) (1.84, 7.60) AMI recurrence NP 4.71 (1.72, 12.89) (0.55, 10.06) PP (9.30, 50.65) (8.13, 54.30) Death/AMI NP 3.33 (1.87, 5.96) (1.65, 6.70) PP 8.19 (4.77, 14.05) (4.97, 15.35)
6 Clinical Chemistry 52, No. 11, Days since presentation Table 3. Hazard ratios compared with either the NP group or the intermediate ctni group ( g/l). Outcome AMI classification Hazard ratio relative to NP (95% CI) Marker g/l Hazard ratio relative to ctni g/l (95% CI) 30 Death NN 0.61 (0.17, 2.22) (0.05, 0.98) PP 1.29 (0.28, 5.89) (0.24, 2.96) AMI recurrence NN 0.05 (0.01, 0.45) 0.04 No events PP 4.82 (1.76, 13.21) (1.59, 30.16) Death/AMI NN 0.24 (0.09, 0.65) (0.03, 0.46) PP 3.57 (1.61, 7.94) (1.20, 6.59) 120 Death NN 0.21 (0.09, 0.50) (0.06, 0.51) PP 0.85 (0.34, 2.14) (0.52, 2.60) AMI recurrence NN 0.13 (0.03, 0.53) (0.01, 0.76) PP 5.98 (2.41, 14.86) (2.05, 23.00) Death/AMI NN 0.15 (0.07, 0.33) (0.04, 0.29) PP 2.50 (1.38, 4.55) (1.29, 4.67) 360 Death NN 0.35 (0.18, 0.67) (0.16, 0.73) PP 0.87 (0.39, 1.95) (0.63, 2.54) AMI recurrence NN 0.21 (0.08, 0.58) (0.10, 1.82) PP 4.61 (2.12, 10.03) (2.71, 29.45) Death/AMI NN 0.30 (0.17, 0.54) (0.15, 0.61) PP 2.46 (1.42, 4.25) (1.48, 4.69) are in contrast to previous findings that suggested that the risks of the group positive by ESC/ACC criteria only are greater than or equivalent to the risks of the group positive by both WHO and ESC/ACC criteria (4, 5). Specifically, these data vary from the report of Salomaa et al. (5), who reported that the all-cause mortality rate in patients meeting only the new AMI definition was worse than in patients meeting both criteria. Their population consisted of suspected MI events included in the Finnish myocardial infarction register study, FINAMI, during Troponin concentrations were used for diagnosis, but troponin did not uniformly determine management. Their patients who met only the ESC/ACC criteria were older and had diabetes more often, but most did not receive urgent revascularization. Troponin values were not available in our study population, and aggressive revascularization was not used widely at that time except for patients with STEMIs. Thus, the outcomes in our study are less biased by the use of modern therapies. Our NP group represents a previously undiagnosed subpopulation at equal risk for all-cause mortality but with a slightly lower AMI recurrence rate than the WHO-defined AMI population (Table 3), despite the fact our AMI recurrence rate in 1997 was based on the less sensitive WHO AMI criteria. We expect that this effect would have been greater had the ESC/ACC definition been used in 1997 for Table 4. Logistic regression model for prediction of AMI recurrence or death within 1 year of presentation based on either presentation or peak ctni concentration. A. AMI recurrence within 1 year Reference g/l Effect g/l OR, 95% CI C-Statistic Presentation value (3.17, 30.31) (1.91, 25.81) (6.71, 38.47) Peak value (0.64, 12.79) (11.00, 81.73) B. Death within 1 year Reference g/l Effect g/l OR, 95% CI C-Statistic Presentation value (0.89, 6.62) (1.61, 12.85) (0.44, 3.55) Peak value (1.61, 8.75) (2.00, 9.35)
7 2034 Kavsak et al.: Health Outcomes by AMI Definitions AMI classification (8). These data are consistent with the increased frequency of recurrent infarction and mortality over time in patients with non-stemi, which are enriched in our population (16). Patients with STEMI have a greater initial hazard but thereafter tend to have a more stable course (16, 17). In most series, by 6 months after presentation mortality rates for non-stemi and STEMI patients are similar (17). In addition, in keeping with the literature on acute coronary syndromes, our data confirm that a higher peak ctni is associated with a greater risk for death/ami. Our observation of a concentration-dependent effect was in an unselected population of all presenting patients and did not exclude STEMI patients. Studies by Kontos et al. (18) and Sabatine et al. (19) had similar findings, although their studies excluded STEMI patients who met criteria for fibrinolytic treatment, thereby lessening the overall severity of outcomes in their high-ctni group, which was analogous to our PP group or our high-peak ctni group. We did not exclude these patients, and therefore our PP and high-peak ctni groups might have had more severe outcomes. Our data are different from those of some acute coronary syndrome therapy trials, which have tended to select higher-risk patients and cannot be extrapolated easily to societal screening. For example, Morrow et al. (20) used the same AccuTnI assay in a population in which 64% of the patients had ctni values at or above the 99th percentile. Our data set comes from a nonselected cohort of emergency department patients in whom the frequency of ctni elevations at or above the 99th percentile was 37%, which is closer to the AMI prevalence in this population (8, 21). Thus, the present study provides new information from a population more representative of patients who present to emergency departments. In a troponin-naïve population, diagnoses made according to only the more sensitive ESC/ACC criteria identify patients with intermediate risks (lower than the risks in patients positive by WHO criteria), a finding that restores the expected relationship of biomarker concentrations, severity of disease, and prognosis (22, 23). Our study has several limitations. We are unable to discern the cause of death in our study population; therefore, we cannot compare the rates for cardiovascular deaths in our derived cohorts. Also, our small study population and consequent scarcity of events (i.e., AMI and/or death) not only led to wide confidence intervals around the hazard ratio estimates but also prevented secondary analyses, such as those based on sex. Our study demonstrates a difference in the frequency of adverse events during follow-up, related to the magnitude of the peak concentration of ctni and AMI definition used. However, the absolute adverse event frequencies in our study should not be extrapolated to the present. Currently, on the basis of the ESC/ACC definition, most of the patients with increased troponin values, including those in the group with only troponin increases, would be identified as high-risk patients (8) and would receive early invasive interventions and more potent antiplatelet/ antithrombin therapy, which in the vast majority of trials has been found to lower rates of adverse events (6). In conclusion, these data, from an unselected troponinnaïve population, before the identification and treatment of patients with non-stemi for aggressive intervention, validates the use of the ESC/ACC criteria for evaluating AMI in the population at large. This work was supported by the Research Trust Small Grants program of the Ontario Association of Medical Laboratories. The AccuTnI reagent was contributed for the study by an unrestricted grant from Beckman-Coulter Inc. References 1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000;36: Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, et al. AHA Scientific Statement. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. Circulation 2003;108: Lin JC, Apple FS, Murakami MM, Luepker RV. Rates of positive cardiac troponin I and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes. Clin Chem 2004;50: Trevelyan J, Needham EW, Smith SC, Mattu RK. Impact of the recommendations for the redefinition of myocardial infarction on diagnosis and prognosis in an unselected United Kingdom cohort with suspected cardiac chest pain. Am J Cardiol 2004;93: Salomaa V, Koukkunen H, Ketonen M, Immonen-Raiha P, Karja- Koskenkari P, Mustonen J, et al. A new definition for myocardial infarction: what difference does it make? Eur Heart J 2005;26: Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. Can Med Assoc J 2005;173: Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/ American College of Cardiology Consensus Recommendations. Clin Chem 2003;49: Kavsak PA, MacRae AR, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, et al. The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction. Am Heart J 2006;152: MacRae AR, Kavsak PA, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, et al. Assessing the Requirement for the 6-hour interval between specimens in the American Heart Association classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem 2006;52: Venge P, Lindahl B, Wallentin L. New generation cardiac troponin I assay for the access immunoassay system. Clin Chem 2001; 47:
8 Clinical Chemistry 52, No. 11, Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-b-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50: Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004;50: Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45: Apple FS, Parvin CA, Buechler KF, Christenson RH, Wu AH, Jaffe AS. Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem 2005;51: Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 2002;144: Furman MI, Dauerman HL, Goldberg RJ, Yarzebski J, Lessard D, Gore JM. Twenty-two year (1975 to 1997) Trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-q-wave myocardial infarction: a multi-hospital, communitywide perspective. J Am Coll Cardiol 2001;37: Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. Circulation 1998;98: Kontos MS, Shah R, Fritz LM, Anderson FP, Tatum JL, Ornato JP, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 2004;43: Sabatine MS, Morrow DA, McCabe CH, Antman EM, Gibson CM, Cannon CP. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-st-elevation myocardial infarction. Am Heart J 2006;151: Morrow DA, Rifai N, Sabatine MS, Ayanian S, Murphy SA, de Lemos JA, et al. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem 2003;49: Kavsak P, Lustig V, MacRae AR. Clinical evaluation of the Beckman Coulter AccuTnI assay for the early detection of acute myocardial infarction [Abstract]. Clin Chem 2004;50:A Geltman EM, Ehsani AA, Campbell MK, Schechtman K, Roberts R, Sobel BE. The influence of location and extent of myocardial infarction on long-term ventricular dysrhythmia and mortality. Circulation 1979;60: Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, et al. Association between minor elevations of creatine kinase-mb level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA 2000; 283:
Papers in Press. Published March 23, 2007 as doi: /clinchem
Papers in Press. Published March 23, 2007 as doi:10.1373/clinchem.2006.084715 The latest version is at http://www.clinchem.org/cgi/doi/10.1373/clinchem.2006.084715 Clinical Chemistry 53:4 547 551 (2007)
More informationAnalytical performance of the i-stat cardiac troponin I assay
Clinica Chimica Acta 345 (2004) 123 127 www.elsevier.com/locate/clinchim Analytical performance of the i-stat cardiac troponin I assay Fred S. Apple a, *, MaryAnn M. Murakami a, Robert H. Christenson b,
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationRapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.
Rapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R. Published in: American Journal of Clinical Pathology DOI: 10.1309/AJCPA4G8AQOYEKLD
More informationPharmacologyonline 2: (2010) Newsletter Kakadiya and Shah
ROLE OF CREATINE KINASE MB AND LACTATE DEHYDROGENASE IN CARDIAC FUNCTION A REVIEW Jagdish Kakadiya*, Nehal Shah Department of Pharmacology, Dharmaj Degree Pharmacy College, Petlad- Khambhat Road, Dharmaj,
More informationHigh Sensitivity Troponin Improves Management. But Not Yet
High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationTroponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
More informationThe Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients
The Journal of International Medical Research 2003; 31: 76 83 The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients S VATANSEVER 1, V AKKAYA
More informationhs-c Tn I high sensitivity troponin I <17 min
hs-c Tn I high sensitivity troponin I IFCC & ESC compliant 0/ h NSTEMI rule-out / rule-in algorithm POCT whole blood/plasma Results in < 7 minutes
More information10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department
More informationFrequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.08.062
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationTIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationOverall Changes of the Universal Myocardial Infarction Definition
Overall Changes of the Universal Myocardial Infarction Definition Professor Kristian Thygesen, FESC, FACC, FAHA Aarhus University Hospital, Aarhus, DK Co-Chairman of The Global MI Task Force Declaration
More informationCardiac-specific troponin I (ctni) has been under intensive
Original Articles Association of Mild Transient Elevation of Troponin I Levels With Increased Mortality and Major Cardiovascular Events in the General Patient Population G. Steinar Gudmundsson, MD; Stephen
More informationA New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory
e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationTiming of angiography for high- risk ACS
Timing of angiography for high- risk ACS Christian Spaulding, MD, PhD, FESC, FACC Cardiology Department Cochin Hospital, Inserm U 970 Paris Descartes University Paris, France A very old story. The Interventional
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationRuling out acute myocardial infarction early with two serial creatine kinase-mb mass determinations
European Heart Journal (1999) 20, 967 972 Article No. euhj.1998.1449, available online at http://www.idealibrary.com on Ruling out acute myocardial infarction early with two serial creatine kinase-mb mass
More informationP1: OTE/SPH P2: OTE BLUK084-Adams April 13, :13 PART 1. Cardiac troponins
PART 1 Cardiac troponins 1 2 CHAPTER 1 Basics of cardiac troponin: practical aspects of assays, potential analytical confounders, and clinical interpretation Fred S. Apple Case 1 Following an episode of
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationEarly risk stratification is essential in the management of
Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;
More informationPost-Procedural Myocardial Injury or Infarction
Post-Procedural Myocardial Injury or Infarction Hugo A Katus MD & Evangelos Giannitsis MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Conflict of Interest:
More informationEDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS
SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Early rule out or diagnosis of acute myocardial infarction: High-sensitivity troponin tests (Elecsys troponin T high-sensitive, ARCHITECT STAT highsensitivity
More informationOP Chest Pain General Data Element List. All Records All Records. All Records All Records All Records. All Records. All Records.
Material inside brackets ([and]) is new to this Specifications Manual version. Hospital Outpatient Quality Measures Chest Pain (CP) Set Measure ID # OP-4 * OP-5 * Measure Short Name Aspirin at Arrival
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationPeri-operative Troponin Measurements - Pathophysiology and Prognosis
Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationGUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT
GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT sponsored by TROPONIN OVERVIEW TROPONIN DETECTION IN NORMAL AND DISEASE STATES1 The detection of
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHigh-Sensitivity Cardiac Troponin in Suspected ACS
15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care
More informationOriginal Article Decision limit for troponin I and assay performance Abstract Address Background Correspondence Methods Results Conclusions
Decision limit for troponin I and assay performance Paul Sheehan, John Blennerhassett and Samuel D Vasikaran Original Article Abstract Address Core Clinical Pathology and Biochemistry Division of Laboratory
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationJournal of the American College of Cardiology Vol. 41, No. 3, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 3, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02824-3
More informationNew diagnostic markers for acute coronary syndromes
New diagnostic markers for acute coronary syndromes - Nye diagnostiske markørerer for akutt iskemisk hjertesykdom Bertil Lindahl, Professor Cardiology, Uppsala University and Uppsala Clinical Research
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationEarly diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong
Hong Kong Journal of Emergency Medicine Early diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong CH Ho, W Cheng, G Chu, HF Ho Introduction: Cardiac
More informationAcute Coronary Syndromes
High-sensitivity Troponins Difficult Friends in Acute Coronary Syndromes Roland Klingenberg, Christian M Matter, 2 Christophe Wyss, Danielle Hof, Arnold von Eckardstein and Thomas F Lüscher 6. Clinical
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationNon-commercial use only
Emergency Care Journal 2019; volume 15:7798 Determinants of troponin T and I elevation in old patients without acute coronary syndrome Antonio Di Micoli, 1 Chiara Scarciello, 1 Stefania De Notariis, 1
More informationBioRemarkable Symposium
BACC BioRemarkable Symposium Acute Myocardial infarction Stefan Blankenberg University Heart Center Hamburg London, September 7th, 2017 Universitätsklinikum Hamburg-Eppendorf Third Universal-Definition
More informationCardiac Troponin I Levels and Clinical Outcomes in Patients With Acute Coronary Syndromes The Potential Role of Early Percutaneous Revascularization
Journal of the American College of Cardiology Vol. 34, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00434-9 Cardiac
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationDiagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15
Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, e, ARCHITECT STAT T High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics guidance
More informationÄr dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
More informationSafe discharge from the cardiac emergency room with a rapid rule-out myocardial infarction protocol using serial CK-MB mass
Heart 2001;85:143 148 143 Department of Cardiology, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands R Bholasingh R J de Winter J C Fischer R W Koster RJGPeters G T Sanders Correspondence
More informationOriginal Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice
Am J Cardiovasc Dis 2012;2(3):248-252 www.ajcd.us /ISSN:2160-200X/AJCD1204002 Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice Angela
More informationDiagnostics consultation document
National Institute for Health and Care Excellence Diagnostics consultation document Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive,
More informationSignificance of QRS duration in non-st elevation myocardial infarction.
Thomas Jefferson University Jefferson Digital Commons Cardiology Faculty Papers Department of Cardiology 5-6-2015 Significance of QRS duration in non-st elevation myocardial infarction. Chinualumogu Nwakile
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationHigh-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective Evaluation
Clinical Chemistry 61:7 983 989 (2015) Proteomics and Protein Markers High-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective
More informationPrognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris C T KASANUKI, MD, FJCC
C T Prognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris Hiroyuki Yukio Hiroshi TANAKA, MD TSURUMI, MD KASANUKI, MD, FJCC Abstract Objectives. The prognosis
More informationSpeaker: Richard Heitsman, MICT, C-POC-AACC. Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America.
Speaker: Richard Heitsman, MICT, C-POC-AACC Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America. Upon completion the participant will be able to o Review current and evolving
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationOutcomes of Hospitalized Patients with Non-Acute Coronary Syndrome and Elevated Cardiac Troponin Level
CLINICAL RESEARCH STUDY Outcomes of Hospitalized Patients with Non-Acute Coronary Syndrome and Elevated Cardiac Troponin Level Edward O. McFalls, MD, PhD, a Greg Larsen, MD, b Gary R. Johnson, MS, f Fred
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationClinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome
CLINICAL SCIENCE Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome Jinchuan Yan, Cuiping Wang, Rui Chen, Haibing Yang The Affiliated Hospital of Jiangsu
More informationCurrent Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN
Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure
More informationJournal of the American College of Cardiology Vol. 40, No. 6, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 6, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02119-8
More informationPrognostic Value of Biomarkers During and After Non ST-Segment Elevation Acute Coronary Syndrome
Journal of the American College of Cardiology Vol. 54, No. 4, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.056
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationA. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN
More informationMethods The PARAGON-B trial
Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial Kenneth W. Mahaffey, MD, a Matthew T. Roe, MD, a Christopher K. Dyke,
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationTroponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Economic consequences of routine coronary angiography in low- and intermediate-risk patients with unstable angina pectoris Desai A S, Solomon D H, Stone P H, Avorn J Record Status This is a critical abstract
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMost patients ( 85%) who present to an emergency department
Ninety-Minute Exclusion of Acute Myocardial Infarction By Use of Quantitative Point-of-Care Testing of Myoglobin and Troponin I James McCord, MD; Richard M. Nowak, MD, MBA; Peter A. McCullough, MD, MPH;
More informationNew universal definition of myocardial infarction
New universal definition of myocardial infarction L. K. Michalis, ΜRCP, FESC Professor of Cardiology, University of Ioannina Changing Criteria for definition of MI Primarily clinical & ECG approach First
More informationA 45-Year-Old Man with Substantial Chest Pain
Case 1 A 45-Year-Old Man with Substantial Chest Pain Fred S. Apple History of Current Presentation The subject is a 45-year-old African-American male who presents with a chief complaint of substantial
More informationFast Track Guideline for Patients with Acute Coronary Syndrome at Saraburi Hospital
Fast Track Guideline for Patients with Acute Coronary Syndrome at Saraburi Hospital Pitha Promlikitchai, MD Cardiovascular Unit, Department of Medicine, Saraburi Hospital, Saraburi, Thailand Abstract Objective:
More informationAvailable online at
152 Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 45, no. 2, 2015 The Distribution of Abbott High-Sensitivity Troponin I Levels in Korean Patients with Chest Pain
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationCardiovascular diseases are the leading cause of morbidity and mortality
ORIGINAL ARTICLE Thrombolysis in myocardial infarction (TIMI) risk score validation in Saudi Arabia Saad Al-Bugami, Faisal Al-Husayni, Samer Alamri, Rakan Aljedaani, Mohammad Zwawy, Abdulaziz Al-Zahrani
More informationTreatment strategies and risk stratification in acute coronary syndromes Damman, P.
UvA-DARE (Digital Academic Repository) Treatment strategies and risk stratification in acute coronary syndromes Damman, P. Link to publication Citation for published version (APA): Damman, P. (2013). Treatment
More informationNew Risk Score for Patients With Acute Chest Pain, Non ST-Segment Deviation, and Normal Troponin Concentrations A Comparison With the TIMI Risk Score
Journal of the American College of Cardiology Vol. 46, No. 3, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.04.037
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More informationImpact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction
doi: 10.2169/internalmedicine.8510-16 http://internmed.jp ORIGINAL ARTICLE Impact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction Taro Ichise, Hayato
More informationMode of admission and its effect on quality indicators in Belgian STEMI patients
2015 Mode of admission and its effect on quality indicators in Belgian STEMI patients Prof dr M Claeys National Coordinator STEMI registry 29-6-2015 Background The current guidelines for the management
More informationLow concentrations of high-sensitivity troponin T at presentation to the
Title Page Low concentrations of high-sensitivity troponin T at presentation to the Emergency Department. Running head: Early rule-out using high-sensitivity troponin T Article Type: Letter to the Editor
More informationDiagnostic Implications of an Elevated Troponin in the Emergency Department
Diagnostic Implications of an Elevated Troponin in the Emergency Department The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation
More informationArticle in press - uncorrected proof
Clin Chem Lab Med 2006;44(6):768 773 2006 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2006.125 2006/60 Integration between the Tele-Cardiology Unit and the central laboratory: methodological
More informationEvaluation of a Rapid Whole Blood ELISA for Quantification of Troponin I in Patients with Acute Chest Pain
Clinical Chemistry 45:10 1789 1796 (1999) Enzymes and Protein Markers Evaluation of a Rapid Whole Blood ELISA for Quantification of Troponin I in Patients with Acute Chest Pain Christopher Heeschen, 1*
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationUniversity of Groningen. Somatic depression in the picture Meurs, Maaike
University of Groningen Somatic depression in the picture Meurs, Maaike IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationPlasma levels of cardiac troponin (ctn) provide important
Elevated Troponin I Level on Admission Is Associated With Adverse Outcome of Primary Angioplasty in Acute Myocardial Infarction Shlomo Matetzky, MD; Tali Sharir, MD; Michelle Domingo, BS; Marko Noc, MD;
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More information